Our Services

Icon1

Preclinical Development

Read More

Clinical Development

Read More

Immuno-oncology Development & Strategy

Read More

Clinical Pharmacology Strategy & Development

Read More

FDA & Global Regulatory

Read More

Strategic Due Diligence

Read More

Pharmacometrics

Read More

Pharmacokinetics

Read More

Project Optimus Services

Read More
image

Focus on Immuno-Oncology Development & Strategy

Immuno-oncology is truly one of the most exciting, while in the same time very challenging areas of oncology research and development. Immuno-oncology development attempts to utilize the full power of one’s immune system to be able to fight the cancer. These molecules are developed to stimulate the immune system to recognize and to attack the cancerous cells.

Our Drug Development Experience

Icon1
Preclinical Development
  • Early Research and Pharmacology, Designs and Interpretation of results
  • Toxicology Study designs, data analysis and reporting
Icon 2
Clinical Development
  • Translational Medicine
    • Preclinical efficacy/safety interpretation, Starting dose rationale
  • Early and Late development
    • Study designs, protocol writing and building, CRO collaboration
Icon 3
Immuno-oncology development
  • Translational Medicine, Starting dose setting
  • Early and Late development
    • Early Research and Pharmacology, Designs and Interpretation of results
    • Toxicology Study designs, data analysis and reporting
    • Translational Medicine
      • Preclinical efficacy/safety interpretation, Starting dose rationale
    • Study designs, protocol building, CRO collaboration
  • HA interactions
Icon 4
Global Regulatory Agencies Engagement and Interactions
  • HA meeting preparations and interactions
  • Evaluate and provide guidance on all aspects of regulatory strategy for compound development

 

Icon 5
Clinical Pharmacology Development and Strategy Focus
  • Phase I, Phase II, comparability studies with manufacturing changes to materials/CMC assessment.
Strategic Due Diligence
  • Early and Late development program risk assessment